Coiled Therapeutics plc

COIL · AIM · Health Care · mcap £26m · 6.1p

Beta Briefing, track record and signals & risks are not ready for Coiled Therapeutics plc yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

Financials · LTM to 30 Jun 26

Source: results 28 Sep 26 ↗

Revenue: £0k
Operating profit: −£5.6m
Net income: −£6.7m
Free cash flow: −£3.2m
Net cash: £5.0m
Market cap: £26.1m
EV / EBIT: –
FCF yield: −12.1%
Price / book: 0.5×

Latest half-year · H1 26 vs H1 25 results 28 Sep 26 ↗

Operating profit: −£2.7m
Net income: −£3.9m
Cash from operations: −£2.9m

Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Key figures As reported

Income statement Balance sheet Cash flow

Annual Half-yearly

Standardised line items in £m, comparable across companies; when a later report restated a period, the later figure is shown and marked ^r (hover for the figure first reported). Italic = calculated (LTM, H2 = FY − H1); a year of other than 12 months is marked (15m). Hover a value for its source.

Latest report: H1 26 (six months to 30 Jun 26), published 28 Sep 26 · read the results ↗

Source ↗

	Unaudited 6 Month Period ended 30 June 2026 £	Unaudited 6 Month Period ended 30 June 2025 £	Audited Year ended 31 December 2025 £
Revenue	-	-	-
Cost of goods	-	-	-
Gross profit	-	-	-
Other income	-	-	16,178
Administrative expenses	(831,624)	(347,750)	(683,653)
Research and development	(1,257,095)	(142,956)	(149,529)
Impairment	-	-	(2,486,944)
Relisting and acquisition expenses	(632,161)	-	-
Loss on disposal of assets	-	-	(39,794)
Depreciation	-	(2,702)	(4,954)
Operating loss	(2,720,880)	(493,408)	(3,348,696)
Interest receivable	-	-	-
Interest payable	-	(22,160)	(37,973)
Finance expense	(1,822)	(16,466)	(17,292)
Share based payments	(1,128,977)	-	-
Loss before taxation	(3,851,679)	(532,034)	(3,403,961)
Income tax	-	41,887	41,887
Total loss for the period attributable to equity holders of the Company	(3,851,679)	(490,147)	(3,362,074)
Other comprehensive (loss)/ income	(5,070)	22,980	11,344
Total comprehensive loss attributable to equity holders of the Company	(3,856,749)	(467,167)	(3,350,730)
Basic and diluted earnings per ordinary share (pence)	(1.66)	(3.32)	(21.89)

Source ↗

	Unaudited As at 30 June 2026 £	Unaudited As at 30 June 2025 £	Audited As at 31 December 2025 £
Assets
Non-current assets
Property, Plant & Equipment	-	42,046	-
Intangible assets	43,404,751	3,861,976	2,574,650
Total non-current assets	43,404,751	3,904,022	2,574,650
Current assets
Trade and other receivables	372,199	31,203	40,359
Cash and cash equivalents	5,099,604	182,923	78,054
Asset held for sale	-	1,543,893	-
Total current assets	5,471,803	1,758,019	118,413
Total assets	48,876,554	5,662,041	2,693,063
Equity and liabilities
Equity attributable to shareholders
Share capital	5,741,451	1,574,440	1,637,263
Share premium	39,193,432	4,733,788	4,761,516
Share capital to issue	-	-	459,736
Share based payments reserve	10,247,220	407,000	179,332
Called up share capital	1,837,974	-	-
Merger relief reserve	3,700,000	3,700,000	3,700,000
Retained deficit	(12,103,779)	(5,755,219)	(8,399,477)
Currency translation reserve	76,205	92,911	81,275
Total equity	48,692,503	4,752,920	2,419,645
Liabilities
Non-Current liabilities
Deferred tax liabilities	-	281,911	-
Total non-current liabilities	-	281,911	-
Current liabilities
Trade and other payables	92,063	133,687	273,418
Borrowings	91,988	383,650	-
Liabilities held for sale	-	109,873	-
Total current liabilities	184,051	627,210	273,418
Total liabilities	184,051	909,121	273,418
Total equity and liabilities	48,876,554	5,662,041	2,693,063

Source ↗

	Unaudited 6 Month Period ended 30 June 2026 £	Unaudited 6 Month Period ended 30 June 2025 £	Audited Year ended 31 December 2025 £
Cash flow from operating activities
Loss before income tax	(3,851,679)	(532,034)	(3,403,961)
Adjustments for
Share based payment	1,216,227	-	-
Foreign exchange	(5,306)	20,873	(42,005)
Finance charge	1,822	16,466	17,292
Interest expense	-	22,160	37,973
Taxation	-	41,887	41,887
Depreciation	-	2,702	4,954
Impairment	-	-	2,486,944
Disposal of assets	-	-	39,794
Changes in working capital
Increase in receivables	(156,839)	(11,799)	(16,530)
Increase / (decrease) in payables	(55,439)	110,203	188,028
Net cash used in operating activities	(2,851,214)	(329,542)	(645,624)
Cash flow from investing activities
Assets held for sale	-	(56,865)	-
Net cash used in investing activities	-	(56,865)	-
Cashflows from financing activities
Proceeds from share issue net of fees	7,780,500	236,000	386,001
Borrowings	91,988	-	-
Net cash from financing activities	7,872,488	236,000	386,001
Net increase/(decrease) in cash and cash equivalents	5,021,274	(150,407)	(259,623)
Cash and cash equivalents at beginning of the period	78,054	337,112	337,112
Foreign exchange impact on cash	276	(3,782)	565
Cash and cash equivalents at end of the period	5,099,604	182,923	78,054

Source ↗

	2025 £	2024 £
Revenue	-	-
Cost of Sales	-	(16,000)
	-	(16,000)
Other income	16,178	-
Administrative expenses	(683,653)	(931,642)
Share based payments - directors and senior managers	-	(10,958)
Research and development expenditure	(149,529)	(152,915)
Impairment	(2,486,944)	-
Loss on disposal of assets	(39,794)	-
Depreciation	(4,954)	(5,404)
Operating loss for the year	(3,348,696)	(1,116,919)
Interest receivable	-	-
Interest payable	(37,973)	(44,857)
Finance charge	(17,292)	(52,793)
Loss for the year before taxation	(3,403,961)	(1,214,569)
Taxation	41,887	242,766
Loss for the year	(3,362,074)	(971,803)
Other comprehensive income	11,344	57,251
Total comprehensive loss for the period attributable to equity holders of the parent	(3,350,730)	(914,552)
Loss per share (basic and diluted) attributable to the equity holders (pence)	(2.19)	(0.75)

Source ↗

	2025 £	2024 £
Cash flow from operating activities
Loss before income tax	(3,403,961)	(1,214,569)
Adjustments for
Taxation	41,887	242,766
Interest expense	37,973	44,857
Finance charge	17,292	52,793
Impairment	2,486,944	-
Disposal of assets	39,794	-
Foreign Exchange	(42,005)	54,556
Share based payment	-	21,463
Depreciation	4,954	5,404
Changes in working capital
Decrease / (Increase) in trade and other receivables	(16,530)	130,412
Increase / (Decrease) in trade and other payables	188,028	(121,143)
Net cash used in operating activities	(645,624)	(783,731)
Cash flow from Investing activities
Purchase of Property, Plant & Equipment	-	-
Interest received	-	-
Net cash used in investing activities	-	-
Cash flows from financing activities
Proceeds from convertible loan note	-	584,915
Proceeds from share issue	386,001	-
Interest paid	-	-
Net cash generated from / (used in) financing activities	386,001	584,915
Net decrease in cash and cash equivalents	(259,623)	(198,816)
Cash and cash equivalents at the beginning of the period	337,112	537,322
Foreign exchange impact on cash	565	(1,394)
Cash and cash equivalents at the end of the period	78,054	337,112

	LTM Jun 26	FY 25	FY 24
Revenue to operating profit
Revenue	–	0.0	0.0
Gross profit	0.0	0.0	–
Operating profit	(5.6)	(3.3)	(1.1)
Depreciation (owned assets)	–	(0.0)	(0.0)
Share-based payments	–	0.0	(0.0)
Operating profit to net income
Finance costs	(0.0)	(0.0)	(0.0)
Profit before tax	(6.7)	(3.4)	(1.2)
Tax	0.0	0.0	0.2
Net income (owners)	(6.7)	(3.4)	(1.0)
Per share
EPS basic	(20.2p)	(21.9p)	(0.8p)
EPS diluted	(20.2p)	(21.9p)	(0.8p)

	H1 26	vs H1 25	H2 25	H1 25
Revenue to operating profit
Gross profit	0.0	n/m	0.0	0.0
Operating profit	(2.7)	n/m	(2.9)	(0.5)
Share-based payments	(1.1)	–	–	–
Operating profit to net income
Finance costs	(0.0)	n/m	(0.0)	(0.0)
Profit before tax	(3.9)	n/m	(2.9)	(0.5)
Tax	0.0	n/m	0.0	0.0
Net income (owners)	(3.9)	n/m	(2.9)	(0.5)
Per share
EPS basic	(1.7p)	–	(18.6p)	(3.3p)
EPS diluted	(1.7p)	–	(18.6p)	(3.3p)

	LTM Jun 26	FY 25	FY 24
Operating activities
Cash from operations	(3.2)	(0.6)	(0.8)
Financing activities
Shares issued	7.9	0.4	0.0

	H1 26	vs H1 25	H2 25	H1 25
Operating activities
Cash from operations	(2.9)	n/m	(0.3)	(0.3)
Financing activities
Shares issued	7.8	n/m	0.2	0.2

	30 Jun 26	31 Dec 25	31 Dec 24
Non-current assets
Other intangibles	43.4	2.6	–
Property, plant & equipment	0.0	0.0	–
Non-current assets	43.4	2.6	–
Current assets
Trade receivables	0.4	0.0	–
Cash	5.1	0.1	0.3
Current assets	5.5	0.1	–
Total assets	48.9	2.7	–
Current liabilities
Trade payables	0.1	0.3	–
Borrowings, current	0.1	0.0	–
Current liabilities	0.2	0.3	–
Non-current liabilities
Non-current liabilities	0.0	0.0	–
Total liabilities	0.2	0.3	–
Equity
Total equity	48.7	2.4	–

	30 Jun 26	31 Dec 25	30 Jun 25	31 Dec 24
Non-current assets
Other intangibles	43.4	2.6	3.9	–
Property, plant & equipment	0.0	0.0	0.0	–
Non-current assets	43.4	2.6	3.9	–
Current assets
Trade receivables	0.4	0.0	0.0	–
Cash	5.1	0.1	0.2	0.3
Current assets	5.5	0.1	1.8	–
Total assets	48.9	2.7	5.7	–
Current liabilities
Trade payables	0.1	0.3	0.1	–
Borrowings, current	0.1	0.0	0.4	–
Current liabilities	0.2	0.3	0.6	–
Non-current liabilities
Non-current liabilities	0.0	0.0	0.3	–
Total liabilities	0.2	0.3	0.9	–
Equity
Total equity	48.7	2.4	4.8	–

Read automatically from each results announcement. Check the source before relying on a figure.

Spotted an error in this income statement? Report it

Company filings. Not investment advice.